Hospital Foch

The Pneumology department at Hospital Foch conducts extensive studies in respiratory tract diseases, focusing on conditions such as asthma, chronic obstructive pulmonary disease, interstitial lung disease, and infections of the lower airways. Trials aim to evaluate new therapies, improve diagnostic tools, and enhance long‑term disease management.

• Adult subjects with newly diagnosed nontuberculous mycobacterial lung infection
• Chronic obstructive pulmonary disease (COPD)
• Idiopathic pulmonary fibrosis (IPF)
• Severe eosinophilic asthma
• Sarcoidosis with progressive pulmonary involvement

With 176 active trials and 86 investigators, the site emphasizes testing novel anti‑inflammatory agents, inhaled antibiotics, and personalized treatment algorithms for lung diseases.

A broad oncology program at the center addresses neoplasms across multiple organ systems, including lung, kidney, bladder, breast, and gastrointestinal cancers. Research seeks to determine the effectiveness of targeted therapies, immunotherapies, and innovative combination regimens.

• Advanced non‑small cell lung cancer (including ROS1‑positive and KRAS‑mutated subtypes)
• Metastatic renal cell carcinoma with intermediate‑risk features
• High‑risk non‑muscle invasive bladder cancer after BCG therapy
• ER+/HER2‑ negative early breast cancer following standard endocrine treatment
• Advanced colorectal cancer with KRAS G12C mutation

The oncology portfolio evaluates new checkpoint inhibitors, antibody‑drug conjugates, and molecularly‑targeted agents to improve survival and quality of life for patients.

Cardiovascular research at the site targets acute cardiac injury, cerebrovascular events, and vascular disorders. Trials explore innovative anticoagulants, neuroprotective drugs, and regenerative therapies to reduce mortality and disability.

• Acute myocarditis diagnosed by imaging or biopsy
• Acute ischemic stroke with large core or unknown onset
• Patients undergoing endovascular therapy for large ischemic core stroke
• Aneurysmal subarachnoid hemorrhage management
• STEMI patients receiving pre‑hospital intervention

By enrolling diverse patient populations, the program aims to determine whether novel antithrombotic strategies and cardiac recovery agents can enhance outcomes after acute events.

The institution conducts trials on a range of infectious agents and immune‑modulating approaches, addressing both community‑acquired and transplant‑related infections. Studies evaluate new antimicrobial formulations, antibody therapies, and vaccine‑adjunct strategies.

• Treatment of nontuberculous mycobacterial lung infection with inhaled antibiotics
• Management of uncomplicated candidemia with short‑course therapy
• Dual long‑acting broadly neutralizing antibodies plus ART in primary HIV‑1 infection
• Prophylactic rituximab to prevent EBV primary infection in kidney transplant recipients
• Antibiotic duration comparison for acute pyelonephritis in transplant patients

These investigations seek to improve cure rates, reduce resistance, and enhance immune protection in vulnerable patient groups.

A dedicated program focuses on immune‑mediated and rare diseases, testing biologics and disease‑modifying therapies to control inflammation and prevent organ damage.

• Hypereosinophilic syndrome and severe eosinophilic asthma
• Eosinophilic granulomatosis with polyangiitis (EGPA) treatment
• Management of sarcoidosis with targeted anti‑fibrotic agents
• Relapsing multiple sclerosis with novel disease‑modifying treatments
• Prevention and treatment of antibody‑mediated rejection in organ transplantation

The trials aim to demonstrate safety and efficacy of emerging biologics, offering new therapeutic options for patients with limited alternatives.